Frasier syndrome is a rare genetic disorder characterized by kidney disease. Products associated with this market include genetic testing kits and therapies for treating kidney failure. Frasier syndrome causes gonadal dysgenesis in people with XY chromosomes.
The global Frasier Syndrome Market is estimated to be valued at US$ 141.2 Mn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increased government and non-government funding for rare disease research is fueling the growth of the Frasier Syndrome Market. For instance, the National Organization for Rare Disorders (NORD) awarded a grant of $50,000 in 2019 to researchers working on the mechanisms of Frasier syndrome. In addition, the National Institutes of Health (NIH) invested $2.9 billion towards rare disease research in 2021. Such increased funding is enabling more research related to diagnosis, treatment and management of Frasier syndrome, thereby propelling the market growth.
SWOT Analysis
Strength: Frasier Syndrome market has increased awareness and focus on rare diseases. Detection and diagnosis rates are improving with advancement in genetic testing.
Weakness: Limited treatment options are available for Frasier Syndrome. High cost of care poses challenges for patients.
Opportunity: Growing research and clinical trials provide hope for more effective therapies. Partnerships between pharmaceutical companies and research institutes can help accelerate drug development.
Threats: Small patient pool makes Frasier Syndrome an unattractive area for large pharmaceutical investments. New drug approval process can take significant time and resources.
Key Takeaways
The global Frasier Syndrome market is expected to witness high growth over the forecast period of 2023 to 2030. North America currently dominates market share due to presence of major pharmaceutical companies and advanced healthcare facilities. The region is also leading in clinical trials and research funds for rare diseases.
Europe holds second largest market position supported by rising government expenditure on rare diseases. Additionally, increasing awareness programs by patient advocacy groups and availability of reimbursement raise diagnosis rates.
Key players operating in the Frasier Syndrome market are Ovid Therapeutics, Inc., Sanofi and Denali Therapeutics Inc. Ovid Therapeutics is researching novel treatment through gene silencing technology. Sanofi is a leading pharmaceutical company engaged in multiple drug development programs for rare diseases. Denali Therapeutics is conducting clinical trials for small molecule therapies for Frasier Syndrome.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.